Drug Trial Radar · NCT00617747
Efficacy and Tolerability of Zolmitriptan Nasal Spray
Last checked: Nov 20, 2026Latest source record: Apr 6, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,114
Actual
Start
Sep 2002
Primary completion
Not stated
Study completion Jun 2003
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult subjects with migraine headaches
Conditions
- Migraine
Interventions
ZolmitriptanDrug
5mg Nasal Spray
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in migraine headache pain from severe or moderate to mild or noneTime frame: 15 minutes after the initial dose of trial treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.